The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis
NCT02126683 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2014-04-30
Summary
Hashimoto's thyroiditis (HT) is a common form of autoimmune thyroid disease, which affects up to 2% of general population. The annual incidence of HT worldwide is estimated to be 0.8 - 3.5 cases per 1000 persons. The thyroid gland attacked by a variety of cell- and antibody-mediated immune processes. Various auto-antibodies may be present against TPO and Tg, and ADCC is a substantial factor behind the apoptotic fall-out of HT. Activation of cytotoxic T-lymphocytes in response to cell-mediated immune response affected by helper T-cells is central to thyrocyte destruction. Recent studies showed higher pro-inflammatory cytokines in serum of patients with HT, and suggested HT is associated with regulatory T-cells dysfunction, imbalance of ratio of Th1 cell and Th2 cell, overexpression of Th17 cells.
Several studies suggested that pregnant women with HT, even at euthyroid state had higher risk of spontaneous miscarriage, more frequent post-partum depression and higher depressive, anger, and total mood disturbance risk compared to those without HT. Presence of thyroid auto-antibodies is also associated with negative pregnant outcomes including gestational hypertension, late abortion, fetal death, premature delivery and neonatal respiratory distress. Neonates from mothers with ATD have higher rate of transient hypothyroidism. Children of mothers with ATD had higher risk of positive serum thyroid auto-antibodies and development of goiter and thyroid dysfunction. However, there is no suggested treatment for subjects with HT who have normal thyroid function. Low-iodine diet and regularly follow-up were suggested.
Plaquenil (hydroxychloroquine) is an anti-malarial agent, and has been used to treat several autoimmune diseases, including lupus erythematosus and rheumatoid arthritis for more than a century. It reduced lymphocytes, production of auto-antibodies, cytokines, and immune mediators, NK cell activity, and inhibits antigens presenting to CD4 T-cells of B cells, dendritic cells and monocytes.
This study focuses on the effect of Plaquenil on thyroid auto-antibodies, inflammatory markers, cytokines, and goiter size in euthyroid women with HT.
Conditions
- Hashimoto's Thyroiditis
Interventions
- DRUG
-
Hydroxychloroquine
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
Tien-Shang Huang · National Taiwan University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 35 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-04-30
- Primary Completion
- 2016-02-29
- Completion
- 2016-09-30
Countries
- Taiwan
Study Locations
More Related Trials
-
Hashimotos Thyroiditis and Thyroid Cancer
NCT01428167 ·Status: COMPLETED
-
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
NCT02203682 ·Status: UNKNOWN ·Phase: PHASE2
-
Oxidative Status in Children With Autoimmune Thyroiditis
NCT02318160 ·Status: COMPLETED
-
Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)
NCT01551498 ·Status: COMPLETED ·Phase: PHASE2
-
Thyroxin in Subclinical Hypothyroidism
NCT03712683 ·Status: COMPLETED ·Phase: NA
-
Genetic Study of Antithyroid Drugs Associated Agranulocytosis
NCT01977963 ·Status: UNKNOWN
-
The Impact of Change of Thyroid Antibodies on Hormone Level and Disease Burden in Patients With Hashimoto's Thyroiditis
NCT07048821 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease
NCT01102205 ·Status: COMPLETED
-
The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases
NCT04075851 ·Status: UNKNOWN
-
Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism
NCT01848171 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
NCT07152366 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism
NCT00531713 ·Status: COMPLETED ·Phase: PHASE4
-
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
NCT01295333 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism
NCT01831869 ·Status: UNKNOWN ·Phase: PHASE4
-
Gut Microbiota is Associated With Autoimmune Thyroid Disease
NCT03390582 ·Status: UNKNOWN
-
The Oral Microbiota is Associated With Autoimmune Thyroiditis
NCT03447093 ·Status: UNKNOWN
-
Effect of Photobiomodulation Therapy in Patients With Hashimoto's Thyroiditis
NCT06735040 ·Status: COMPLETED ·Phase: NA
-
The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism
NCT00498238 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet
NCT05949671 ·Status: COMPLETED ·Phase: NA
-
DNA Methylation and Autoimmune Thyroid Diseases
NCT02491567 ·Status: COMPLETED
-
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
NCT07152340 ·Status: RECRUITING ·Phase: PHASE4
-
The Impact of Subclinical Hypothyroidism on Cardiovascular System
NCT04236232 ·Status: UNKNOWN
-
Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy
NCT03178253 ·Status: UNKNOWN
-
Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism
NCT02090907 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
NCT07152392 ·Status: RECRUITING ·Phase: PHASE4